Janus Henderson Group’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$25.2M Buy
224,961
+203,903
+968% +$23.4M 0.01% 589
2026
Q2
$2.42M Hold
21,058
– – ﹤0.01% 1368
2026
Q1
$1.75M Hold
21,058
– – ﹤0.01% 1420
2025
Q4
$1.64M Buy
21,058
+2,750
+15% +$186K ﹤0.01% 1433
2025
Q3
$1.04M Sell
18,308
-1,000
-5% -$45.1K ﹤0.01% 1649
2025
Q2
$842K Sell
19,308
-751,274
-97% -$25.9M ﹤0.01% 1695
2025
Q1
$22.8M Buy
770,582
+393,198
+104% +$14.3M 0.01% 540
2024
Q4
$15.2M Buy
377,384
+362,276
+2,398% +$16.4M 0.01% 644
2024
Q3
$714K Sell
15,108
-3,700
-20% -$163K ﹤0.01% 1848
2024
Q2
$561K Sell
18,808
-267
-1% -$9.24K ﹤0.01% 1934
2024
Q1
$766K Buy
19,075
+19
+0.1% +$680 ﹤0.01% 1797
2023
Q4
$485K Sell
19,056
-35
-0.2% -$626 ﹤0.01% 2002
2023
Q3
$265K Buy
19,091
+21
+0.1% +$422 ﹤0.01% 2248
2023
Q2
$438K Buy
19,070
+12
+0.1% +$344 ﹤0.01% 2053
2023
Q1
$565K Buy
+19,058
New +$615K ﹤0.01% 1942
2022
Q2
– Sell
-5,588
Closed -$236K – 2640
2022
Q1
$236K Buy
5,588
+4
+0.1% +$169 ﹤0.01% 2361
2021
Q4
$355K Buy
+5,584
New +$325K ﹤0.01% 2109
2021
Q2
– Sell
-397,708
Closed -$15.5M – 1641
2021
Q1
$15.5M Buy
+397,708
New +$23.9M 0.01% 831

Other funds holding KYMR

Janus Henderson Group's KYMR Position: Q3 2026 in Review

Janus Henderson Group increased its Kymera Therapeutics (KYMR) stake by 968% in Q3 2026, buying an estimated $23.4M and bringing the position to 224,961 shares worth $25.2M. The position accounts for 0.01% of the portfolio, ranked #589.

Janus Henderson Group first reported a position in KYMR in Q1 2021 and has held it in 18 quarters since. 301 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • Janus Henderson Group held 224,961 shares of Kymera Therapeutics worth $25.2M as of Q3 2026.
  • Janus Henderson Group bought 203,903 Kymera Therapeutics shares in Q3 2026, an estimated $23.4M.
  • Kymera Therapeutics made up 0.01% of Janus Henderson Group's portfolio in Q3 2026, its #589 holding.
  • Janus Henderson Group first reported a position in Kymera Therapeutics in Q1 2021 and has held it in 18 quarters since.
  • 301 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on Janus Henderson Group's 13F filing for Q3 2026, filed 16 Nov 2026.